

## Managing hereditary ATTR (hATTR) amyloidosis

Learn how hATTR amyloidosis develops and find out about treatment options that work to manage the condition.



In hATTR amyloidosis, a change in the transthyretin (TTR) gene causes the TTR protein to misfold and form amyloid deposits across multiple parts of the body, causing a wide range of symptoms. Available therapies work to manage the condition by:



### Decreasing TTR protein

**Decreasing the amount of transthyretin (TTR) protein made in the body**—these treatments can help decrease the amount of amyloid deposits in the body and may result in fewer symptoms



### Binding to TTR proteins

**Binding to TTR proteins**—these treatments can prevent the TTR protein from taking on an abnormal shape and forming deposits in the body



### Liver transplant

**Removing the source of variant TTR**—a liver transplant may be an option for some patients who meet certain eligibility criteria

The Bridge is an Alnylam program designed to help raise awareness and provide education and helpful tools for patients, their families, and their caregivers. Please visit [www.hATTRbridge.com](http://www.hATTRbridge.com) to learn more.

Content sponsored and provided by Alnylam Pharmaceuticals. The Bridge and its associated logos are trademarks of Alnylam Pharmaceuticals, Inc. © 2022 Alnylam Pharmaceuticals, Inc. All rights reserved. TTR-USA-00049